JJ
Janssen’s Crohn’s treatment licensed for UK use
November 16, 2016Research and Development, Sales and Marketing Chrohn's disease, J&J, JJ, Janssen, Johnson & Johnson, Stelara
Janssen, a subsidiary of Johnson & Johnson, has announced that its treatment Stelara (ustekinumab) is now licensed by the European …
Collaboration on new therapeutic vaccine for HIV shows promise
November 10, 2016Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Janssen, Johnson & Johnson
Janssen, part of Johnson & Johnson, released details on 9 November of the results of a new study looking into …
Pfizer sets release date for rival to J&J’s blockbuster drug
October 18, 2016Manufacturing and Production J&J, JJ, Johnson & Johnson, Pfizer, Remicade, inflectra
Pfizer have announced that they will begin shipping their rival to Johnson & Johnson’s Remicade by the end of November. …
Top Ten articles in the Pharma Industry this week
September 16, 2016Medical Communications Bayer, GSK, Gilead, GlaxoSmithKline, J&J, JJ, Pfizer, Roche, Sanofi, Takeda, aspen, google, monsanto
As we come to the end of another week, we’re looking back at an exciting week in the industry; there …
NICE backs BMS’ paclitaxel in ovarian cancer; drops Eli Lilly’s Gemzar, J&J’s Yondelis
April 27, 2016Research and Development, Sales and Marketing BMS, Eli Lilly, J&J, JJ, NICE, ovarian cancer, regulation
The National Institute for Health and Care Excellence (NICE) has backed Bristol-Myers Squibb’s paclitaxel as a treatment for ovarian cancer. …
Focus: Ovarian cancer and the case of elusive cure
April 12, 2016Research and Development J&J, JJ, Pfizer, drug trials, ovarian cancer
Each year, more than 21,000 women in the US are diagnosed with ovarian cancer, according to research and more than …
Tesaro shares rise as J&J buys rights to prostate cancer drug for $85 million
April 6, 2016Business Services, Research and Development, Sales and Marketing Cancer, J&J, JJ, M&A, MA, Tesaro, drug, licence agreement, research
Shares in oncology-focussed Tesaro Inc (Nasdaq: TSRO) jumped Wednesday after the company said pharma major Johnson & Johnson (NYSE: JNJ) …
J&J says psoriasis drug Stelara shows positive results in trials for Crohn’s disease
March 18, 2016Medical Communications, Research and Development Crohn’s disease, J&J, JJ, Stelara, crohn's disease
Johnson & Johnson (NYSE: JNJ) on Friday said a second late-stage trial of its psoriasis drug Stelara (ustekinumab) has shown effectiveness …
FDA strengthens safety warning for J&J’s diabetes drug Invokana
September 14, 2015Sales and Marketing FDA, Food and Drugs Administration, Invokamet, J&J, JJ, Johnson & Johnson, diabetes, invokana, safety warning, type 2 diabetes
Johnson & Johnson has suffered a blow after the FDA strengthened its safety warning for the company’s type 2 diabetes …
Janssen sales follow J&J’s downward trend
July 15, 2015Sales and Marketing J&J, JJ, Johnson & Johnson, Johnson and Johnson, financial results, olysio
Strong sales of its new hepatitis C treatment Olysio were not enough to stop a slump in profits at J&J’s …
J&J to file 10 new key drugs by 2019
May 21, 2015Sales and Marketing J&J, JJ
Johnson & Johnson says it plans to file 10 new products with regulators between 2015 and 2019 with each having …
FDA issues more diabetes drug warnings
May 18, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Boehringer, J&J, JJ, lilly
The FDA has warned that a class of type 2 diabetes drugs manufactured by several big pharma firms could cause …
J&J hands over compassionate use reviews to academics
May 7, 2015Sales and Marketing J&J, JJ, academics, compac, eap, johnson
Johnson & Johnson has struck a ‘first-of-its-kind partnership’ with academic researchers to review requests for compassionate use of its investigational …
J&J strong pharma sales can’t offset Q1 losses
April 15, 2015Sales and Marketing J&J, JJ, Q1, Waldenström's macroglobulinemia, Waldenström’s Macroglobulinemia, Zytiga, abiraterone acetate, financials, ibrutinib, imbruvica
Johnson & Johnson’s pharma division achieved worldwide sales of $7.7 billion in the first quarter of this year – but …
IBM partners with J&J, Apple and Medtronics ‘to transform healthcare’
April 14, 2015Sales and Marketing Apple, J&J, JJ, ibm, medtronics
IT firm IBM has teamed up with pharma giants and tech companies to expand its presence in the health and …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
Long-acting therapies set to reshape HIV treatment market
